TW202308679A - 包含環狀胜肽化合物的製劑及其製造方法 - Google Patents

包含環狀胜肽化合物的製劑及其製造方法 Download PDF

Info

Publication number
TW202308679A
TW202308679A TW111117094A TW111117094A TW202308679A TW 202308679 A TW202308679 A TW 202308679A TW 111117094 A TW111117094 A TW 111117094A TW 111117094 A TW111117094 A TW 111117094A TW 202308679 A TW202308679 A TW 202308679A
Authority
TW
Taiwan
Prior art keywords
compound
composition
preparation
added
formula
Prior art date
Application number
TW111117094A
Other languages
English (en)
Chinese (zh)
Inventor
植戸隆充
久保木友香理
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202308679A publication Critical patent/TW202308679A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111117094A 2021-05-07 2022-05-06 包含環狀胜肽化合物的製劑及其製造方法 TW202308679A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021079015 2021-05-07
JP2021-079015 2021-05-07

Publications (1)

Publication Number Publication Date
TW202308679A true TW202308679A (zh) 2023-03-01

Family

ID=83932759

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111117094A TW202308679A (zh) 2021-05-07 2022-05-06 包含環狀胜肽化合物的製劑及其製造方法

Country Status (12)

Country Link
US (1) US20240366711A1 (enExample)
EP (1) EP4299069A4 (enExample)
JP (2) JP7181442B1 (enExample)
KR (2) KR20230169093A (enExample)
CN (1) CN117241817A (enExample)
AU (1) AU2022270498A1 (enExample)
BR (1) BR112023019622A2 (enExample)
CA (1) CA3219090A1 (enExample)
IL (1) IL306018A (enExample)
MX (1) MX2023013099A (enExample)
TW (1) TW202308679A (enExample)
WO (1) WO2022234850A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI579296B (zh) 2011-12-28 2017-04-21 Chugai Pharmaceutical Co Ltd Cyclization of Peptide Compounds
BR112022007535A2 (pt) 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras
AR125800A1 (es) 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n
KR20250008758A (ko) 2022-05-06 2025-01-15 추가이 세이야쿠 가부시키가이샤 Hras 및 nras에 대한 선택적인 kras 억제 효과를 갖는 고리 화합물
JPWO2024085235A1 (enExample) * 2022-10-20 2024-04-25
AU2024257451A1 (en) * 2023-04-20 2025-10-09 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic peptide compound

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2670418A4 (en) * 2011-02-04 2015-06-17 Aegis Therapeutics Llc ORAL BIO-AVAILABLE PEPTIDARY MATERIAL COMPOSITIONS AND METHOD THEREFOR
EP2681235B1 (en) 2011-03-04 2016-05-04 New York University Hydrogen bond surrogate macrocycles as modulators of ras
TWI579296B (zh) 2011-12-28 2017-04-21 Chugai Pharmaceutical Co Ltd Cyclization of Peptide Compounds
DK3215127T3 (da) 2014-11-07 2021-02-01 Sublimity Therapeutics Ltd Sammensætninger omfattende cyclosporin
EP3442991A4 (en) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. RAS-BINDING PEPTIDES AND METHODS OF USE
US10808010B2 (en) 2016-08-11 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
CN110869544B (zh) 2017-06-09 2024-03-08 中外制药株式会社 膜透过性高的环状肽化合物及包含其的文库
WO2020122182A1 (ja) 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法
BR112022007535A2 (pt) * 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras
AR125800A1 (es) * 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n

Also Published As

Publication number Publication date
JP7181442B1 (ja) 2022-11-30
IL306018A (en) 2023-11-01
MX2023013099A (es) 2023-11-17
CA3219090A1 (en) 2022-11-10
KR102582225B1 (ko) 2023-09-22
EP4299069A4 (en) 2025-03-05
JPWO2022234850A1 (enExample) 2022-11-10
US20240366711A1 (en) 2024-11-07
CN117241817A (zh) 2023-12-15
EP4299069A1 (en) 2024-01-03
KR20230020548A (ko) 2023-02-10
JP2023015334A (ja) 2023-01-31
KR20230169093A (ko) 2023-12-15
BR112023019622A2 (pt) 2023-11-14
AU2022270498A1 (en) 2023-10-05
WO2022234850A1 (ja) 2022-11-10

Similar Documents

Publication Publication Date Title
TW202308679A (zh) 包含環狀胜肽化合物的製劑及其製造方法
EP2310363B1 (en) Anticancer oral formulation
CN1422149A (zh) 药物组合物
JP2002505271A (ja) サイクロスポリン類またはマクロライド含有エマルジョン前濃縮物
TW200302734A (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
EA027869B1 (ru) Стабилизированная композиция такролимуса
KR100678829B1 (ko) 타크로리무스의 경구용 마이크로에멀젼 조성물
AU2008254957A1 (en) Ziprasidone formulations
RS67259B1 (sr) Kompozicije koje aktiviraju piruvat kinazu r (pkr)
CN110958880B (zh) 固体分散制剂
Choi et al. A novel acidic microenvironment microsphere for enhanced bioavailability of carvedilol: Comparison of solvent evaporated and surface-attached system
EP4406546A1 (en) Composition containing peptide compound for use with surfactant
Sabri et al. Formulation and In-Vitro Characterization of Solidified Nebivolol Self-Nanoemulsion using Liquisolid Technique.
WO2004062692A1 (en) Formulation of poorly water-soluble active substances
EA049912B1 (ru) Препарат, содержащий циклическое пептидное соединение, и способы его приготовления
WO1994020143A1 (fr) Inhibiteur d'isomerisation optique
KR101819310B1 (ko) 사이클로스포린을 포함하는 약학 조성물
US20250243176A1 (en) (s)-1-(1-acryloylpiperidin-3-yl)-2-fluoro-5,6,7,8,9,10-hexahydrocyclo hepta[b]indole-4-carboxamide, and related crystalline forms, compositions, and methods thereof
WO2025240802A1 (en) Novel compositions, devices and methods
KR20210009153A (ko) 자가나노유화 약물전달시스템을 이용한 타다라필의 경구용 고형제 조성물 및 이의 제조방법
CN103169657A (zh) 一种含灯盏花素磷脂复合物的自乳化剂及其制备方法和用途
CN115745941B (zh) 阳离子脂质化合物
JP2007512333A (ja) 縮合ピロロカルバゾール含有粒子形成組成物
WO2025235577A1 (en) Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
KR20080034989A (ko) 토포이소머라제 ｉ 억제제７-ｔｅｒｔ-부톡시이미노메틸캄토테신의 마이크로입자조성물